Use of metformin in diseases of aging

Current Diabetes Reports

Volumn 14, Issue 6, 2014, Pages

  Miles, John M ^a   Rule, Andrew D ^a   Borlaug, Barry A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Aging; Chronic kidney disease; Diseases; Heart failure; Lactic acidosis; Metformin; Pharmacotherapy; Type 2 diabetes

Indexed keywords

CREATININE; METFORMIN; ANTIDIABETIC AGENT;

AGING; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; DRUG SAFETY; DRUG USE; HEART FAILURE; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION; FEMALE; MALE; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

AGING; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84901583038     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-014-0490-4     Document Type: Review

References (111)

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care. 1993;16:434-44. (Pubitemid 23046633)
2. Gu K, Cowie CC, Harris MI.Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998;21:1138-45. (Pubitemid 28368522)
3. Haffner SM. Epidemiology of insulin resistance and its relation to coronary artery disease. Am J Cardiol. 1999;84:11J-4.
4. Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation. 2003;107:139-46. (Pubitemid 36070946)
5. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients: the diabetes and aging study. Diabetes Care. 2011;34:1329-36.
6. Werner E, Bell J. CCXIV. The preparation of methylguanidine, and of ββ-dimethylguanidine by the interaction of dicyandiamide, and methylammoniumand dimethylammonium chlorides, respectively. J Chem Soc Trans. 1922;121:1790-4.
7. Banting F, Best C. The internal secretion of the pancreas. J Lab Clin Med. 1922;125:251-66.
8. Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2006;29:1963-72. (Pubitemid 44156663)
9. Home PD. Impact of the UKPDS - an overview. Diabetic Med. 2008;25 Suppl 2:2-8.
10. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65.
11. Holman R, Paul S, Bethel M, Matthews D, Neil H. Ten-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577-89.
12. • Roussel R, Travert F, Pasquet B, Wilson PWF, Smith Jr SC, Goto S, et al. Reduction of atherothrombosis for continued health Registry I: metformin use and mortality among patients with diabetes and atherothrombosis. Arch Intern Med. 2010;170:1892-9. This is an epidemiological study in ∼20,000 patients with type 2 diabetes and cardiovascular disease. In the study, metformin therapy was associated with a 31% lower mortality from heart failure and a 24% lower all-cause mortality.
13. Klip A, Leiter LA. Cellular mechanism of action of metformin. Diabetes Care. 1990;13:696-704. (Pubitemid 20169149)
14. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Int Med. 1999;131:281-303. (Pubitemid 29383658)
15. Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, et al. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994;43:920-8. (Pubitemid 24196426)
16. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-71. (Pubitemid 26177181)
17. Scarpello JH, Hodgson E, Howlett HC. Effect of metformin on bile salt circulation and intestinal motility in type 2 diabetes mellitus. Diabetic Med. 1998;15:651-6. (Pubitemid 28355848)
18. Wu MS, Johnston P, Sheu WH, Hollenbeck CB, Jeng CY, Goldfine ID, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes Care. 1990;13:1-8. (Pubitemid 20024723)
19. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995;333:541-9.
20. Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE. Metabolic effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med. 1995;333:550-4.
21. Makimattila S, Nikkila K, Yki-Jarvinen H. Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. Diabetologia. 1999;42:406-12. (Pubitemid 29148398)
22. Willi SM, Martin K, Datko FM, Brant BP. Treatment of type 2 diabetes in childhood using a very-low-calorie diet. Diabetes Care. 2004;27:348-53. (Pubitemid 38174056)
23. Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M. Relative effects of calorie restriction and weight loss in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1993;77:1287-93. (Pubitemid 23345484)
24. Williamson DF, Thompson TJ, Thun M, Flanders D, Pamuk E, Byers T. Intentional weight loss and mortality among overweight individuals with diabetes. Diabetes Care. 2000;23:1499-504.
25. Sobel BE, Frye R, Detre KM. Bypass Angioplasty Revascularization Investigation 2 Diabetes T: burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Circulation. 2003;107:636-42. (Pubitemid 36176817)
26. Chu NV, Kong APS, Kim DD, Armstrong D, Baxi S, Deutsch R, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care. 2002;25:542-9. (Pubitemid 41103350)
27. Miles JM, Wooldridge D, Grellner WJ, Windsor S, Isley WL, Klein S, et al. Nocturnal and postprandial free fatty acid kinetics in normal and type 2 diabetic subjects: effects of insulin sensitization therapy. Diabetes. 2003;52:675-81. (Pubitemid 36323574)
28. Fendri S, Debussche X, Puy H, Vincent O, Marcelli JM, Dubreuil A, et al. Metformin effects on peripheral sensitivity to insulin in nondiabetic obese subjects. Diabete Metab. 1993;19:245-9. (Pubitemid 23189743)
29. Pentikainen PJ, Neuvonen PJ, Penttila A. Pharmacokinetics of metformin after intravenous and oral administration to man. Eur J Clin Pharmacol. 1979;16:195-202. (Pubitemid 10227380)
30. Proctor WR, Bourdet DL, Thakker DR. Mechanisms underlying saturable intestinal absorption of metformin. Drug Metab Dispos. 2008;36:1650-8.
31. Sirtori CR, Franceschini G, Galli-Kienle M, Cighetti G, Galli G, Bondioli A, et al. Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978;24:683-93.
32. Rule A, Amer H, Cornell L, Taler S, Cosio F, Kremers W, et al. The association between age and nephrosclerosis on renal biopsy among healthy adults. Ann Int Med. 2010;152:561-7.
33. Wetzels J, Kiemeney L, Swinkels D, Willems H, den Heijer M. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int. 2007;72:632-7. (Pubitemid 47312796)
34. Schaeffner E, Ebert N, Delanaye P, Frei U, Gaedeke J, Jakob O, et al. Two novel equations to estimate kidney function in persons aged 70 years or older. Ann Int Med. 2012;157:471-81.
35. Grams M, Juraschek S, Selvin E, Foster M, Inker L, Eckfeldt J, et al. Trends in the prevalence of reduced GFR in the United States: a comparison of creatinine - and cystatin C-based estimates. Am J Kidney Dis. 2013;62:253-60.
36. Glassock RJ, Rule AD. The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli. Kidney Int. 2012;82:270-7.
37. Wang X, Vrtiska TJ, Avula RT, Walters LR, Chakkera HA, Kremers WK, et al. Age, kidney function, and risk factors associate differently with cortical and medullary volumes of the kidney. Kidney Int. 2014;85:677-85.
38. Foley RN, Wang C, Collins AJ. Cardiovascular risk factor profiles and kidney function stage in the US general population: the NHANES III study. Mayo Clin Proc. 2005;80:1270-7. (Pubitemid 41395958)
39. Koro CE, Lee BH, Bowlin SJ. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. Clin Ther. 2009;31:2608-17.
40. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis. 2003;41:1-12. (Pubitemid 36043346)
41. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Op Neph Hypertens. 2011;20:246-57.
42. Howlett HC, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug Saf. 1999;20:489-503. (Pubitemid 29296595)
43. Warren RE, Strachan MWJ, Wild S, McKnight JA. Introducing estimated glomerular filtration rate (eGFR) into clinical practice in the UK: implications for the use of metformin. Diabetic Med. 2007;24:494-7. (Pubitemid 46669323)
44. Earley A, Miskulin D, Lamb EJ, Levey AS, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. Ann Int Med. 2012;156:785-95.
45. Cohen R. The relative risks of different biguanides in the causation of lactic acidosis. Res Clin Forums. 1978;1:125-34.
46. • Ekstrom N, Schioler L, Svensson A-M, Eeg-Olofsson K, Jonasson J, Zethelius B, et al. Effectiveness and safety of metformin in 51, 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register. BMJ Open. 2012;2:e001076. This study of over 50,000 people in the Swedish Diabetes. Registry includes >32,000 individuals on metformin and >4000 with CKD-3. It reports a hazard ratio of 0.85 for infection or acidosis and 0.87 for all-cause mortality vs other agents (both P < 0.05).
47. Vasisht KP, Chen SC, Peng Y, Bakris GL. Limitations of metformin use in patients with kidney disease: are they warranted? Diabetes Obes Metab. 2010;12:1079-83.
48. Nattrass M, Todd PG, Hinks L, Lloyd B, Alberti KG. Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics. Diabetologia. 1977;13:145-52. (Pubitemid 8077637)
49. Davis TM, Jackson D, Davis WA, Bruce DG, Chubb P. The relationship between metformin therapy and the fasting plasma lactate in type 2 diabetes: the Fremantle Diabetes Study. Brit J Clin Pharm. 2001;52:137-44. (Pubitemid 32863070)
50. van der Meer RW, Rijzewijk LJ, de Jong HWAM, Lamb HJ, Lubberink M, Romijn JA, et al. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. Circulation. 2009;119:2069-77.
51. Salpeter SR, Greyber E, Pasternak GA, Salpeter EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010:CD002967.
52. Lalau JD, Lacroix C, Compagnon P, de Cagny B, Rigaud JP, Bleichner G, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care. 1995;18:779-84.
53. Galea M, Jelacin N, Bramham K, White I. Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose. Brit J Anaesth. 2007;98:213-5. (Pubitemid 47072000)
54. Miller DK, Brinson AJ, Catalano G, Catalano MC. Lactic acidosis, hypotension, and sensorineural hearing loss following intentional metformin overdose. Curr Drug Safety. 2011;6:346-9.
55. Perrone J, Phillips C, Gaieski D. Occult metformin toxicity in three patients with profound lactic acidosis. J Emerg Med. 2011;40:271-5.
56. Rifkin SI, McFarren C, Juvvadi R, Weinstein SS. Prolonged hemodialysis for severe metformin intoxication. Ren Fail. 2011;33:459-61.
57. Wills BK, Bryant SM, Buckley P, Seo B. Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med. 2010;28:857-61.
58. Sambol NC, Chiang J, Lin ET, Goodman AM, Liu CY, Benet LZ, et al. Kidney function and age are both predictors of pharmacokinetics of metformin. J Clin Pharm. 1995;35:1094-102.
59. Bardin C, Nobecourt E, Larger E, Chast F, Treluyer J-M, Urien S. Population pharmacokinetics of metformin in obese and nonobese patients with type 2 diabetes mellitus. Eur J Clin Pharm. 2012;68:961-8.
60. Arias E, Anderson RN, Kung H-C, Murphy SL, Kochanek KD. Deaths: final data for 2001. Natl Vital Stat Rep. 2003;52:1-115.
61. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. New Engl JMed. 2006;355:251-9. (Pubitemid 44079340)
62. Chamberlain A, McNallan S, Dunlay S, Spertus J, Redfield M, Moser D, et al. Physical health status measures predict all-cause mortality in patients with heart failure. Circ Heart Fail. 2013;6:669-75.
63. Dunlay S, Gerber Y, Weston S, Killian J, Redfield M, Roger V. Prognostic value of biomarkers in heart failure: application of novel methods in the community. Circ Heart Fail. 2009;2:393-400.
64. Borlaug BA, Melenovsky V, Russell SD, Kessler K, Pacak K, Becker LC, et al. Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation. 2006;114:2138-47. (Pubitemid 44747894)
65. Mohammed S, Borlaug B, Roger V, Mirzoyev S, Rodeheffer R, Chirinos J, et al. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail. 2012;5:710-9.
66. van Heerebeek L, Franssen C, Hamdani N, Verheugt F, Somsen G, Paulus WJ. Molecular and cellular basis for diastolic dysfunction. Circ Heart Fail. 2012;9:293-302.
67. Borlaug B, Redfield M, Melenovsky V, Kane G, Karon B, Jacobsen S, et al. Longitudinal changes in left ventricular stiffness: a community-based study. Circ Heart Fail. 2013;6:944-52.
68. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care. 2004;27:1879-84. (Pubitemid 38989226)
69. De Groote P, Lamblin N, Mouquet F, Plichon D, McFadden E, Van Belle E, et al. Impact of diabetes mellitus on long-term survival in patients with congestive heart failure. Eur Heart J. 2004;25:656-62. (Pubitemid 38579494)
70. Borlaug BA, Paulus WJ. Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J. 2011;32:670-9.
71. Diamant M, Lamb HJ, Groeneveld Y, Endert EL, Smit JWA, Bax JJ, et al. Diastolic dysfunction is associated with altered myocardial metabolismin asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol. 2003;42:328-35. (Pubitemid 36851426)
72. Smith CS, Bottomley PA, Schulman SP, Gerstenblith G, Weiss RG. Altered creatine kinase adenosine triphosphate kinetics in failing hypertrophied human myocardium. Circulation. 2006;114:1151-8. (Pubitemid 44386479)
73. Phan TT, Abozguia K, Nallur Shivu G, Mahadevan G, Ahmed I, Williams L, et al. Heart failure with preserved ejection fraction is characterized by dynamic impairment of active relaxation and contraction of the left ventricle on exercise and associated with myocardial energy deficiency. J Am Coll Cardiol. 2009;54:402-9.
74. Lind M, Olsson M, Rosengren A, Svensson A-M, Bounias I, Gudbjornsdottir S. The relationship between glycaemic control and heart failure in 83,021 patients with type 2 diabetes. Diabetologia. 2012;55:2946-53.
75. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. American Heart Association, American Diabetes Association: thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-8. (Pubitemid 37517824)
76. Nichols GA, Koro CE, Gullion CM, Ephross SA, Brown JB. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev. 2005;21:51-7.
77. Yki-Jarvinen H, Ryysy L, Kauppila M, Kujansuu E, Lahti J, Marjanen T, et al. Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82:4037-43. (Pubitemid 27525508)
78. Genev N, Lau I, Willey K, Molyneaux L, Xu Z, Zilkens R, et al. Does insulin therapy have a hypertensive effect in type 2 diabetes? J Cardiovasc Pharmacol. 1998;32:39-41. (Pubitemid 28304691)
79. DeFronzo RA, Cooke CR, Andres R, Faloona GR, Davis PJ. The effect of insulin on renal handling of sodium, potassium, calcium, and phosphate in man. J Clin Invest. 1975;55:845-55.
80. Masoudi FA, Wang Y, Inzucchi SE, Setaro JF, Havranek EP, Foody JM, et al. Metformin and thiazolidinedione use in Medicare patients with heart failure. JAMA. 2003;290:81-5. (Pubitemid 37432869)
81. Liebl A. Challenges in optimal metabolic control of diabetes. Diabetes Metab Res Rev. 2002;18 Suppl 3:S36-41. (Pubitemid 35256583)
82. Neumiller JJ, Setter SM. Pharmacologic management of the older patient with type 2 diabetes mellitus. Am J Ger Pharmacother. 2009;7:324-42.
83. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin. New Engl J Med. 1998;338:265-6. (Pubitemid 28047587)
84. Misbin RI. The phantom of lactic acidosis due to metformin in patients with diabetes. Diabetes Care. 2004;27:1791-3. (Pubitemid 38857465)
85. Inzucchi SE, Masoudi FA, McGuire DK. Metformin in heart failure. Diabetes Care. 2007;30:e129.
86. Pantalone KM, Kattan MW, Yu C, Wells BJ, Arrigain S, Jain A, et al. The risk of developing coronary artery disease or congestive heart failure, and overall mortality, in type 2 diabetic patients receiving rosiglitazone, pioglitazone, metformin, or sulfonylureas: a retrospective analysis. Acta Diabetol. 2009;46:145-54.
87. Eurich DT, Majumdar SR, McAlister FA, Tsuyuki RT, Johnson JA. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005;28:2345-51. (Pubitemid 41384275)
88. Masoudi FA, Inzucchi SE, Wang Y, Havranek EP, Foody JM, Krumholz HM. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation. 2005;111:583-90. (Pubitemid 40216485)
89. • Xie Z, Lau K, Eby B, Lozano P, He C, Pennington B, et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes. 2011;60:1770-8. This study, conducted in rodents, suggests a biochemical basis (improvement in myocardial AMP-activated protein kinase) for improved outcomes in people with heart failure who are treated with metformin.
90. Pocock SJ, McMurray JJV, Dobson J, Yusuf S, Granger CB, Michelson EL, et al. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Eur Heart J. 2008;29:2641-50.
91. Wohlfahrt P, Redfield MM, Lopez-Jimenez F, Melenovsky V, Kane GC, Rodeheffer RJ, et al. Impact of general and central adiposity on ventricular-arterial aging in women and men. JACC Heart Fail. 2014; in press.
92. Alpert MA, Terry BE, Mulekar M, Cohen MV, Massey CV, Fan TM, et al. Cardiac morphology and left ventricular function in normotensive morbidly obese patients with and without congestive heart failure, and effect of weight loss. Am J Cardiol. 1997;80:736-40. (Pubitemid 27413582)
93. Mariotti R, Castrogiovanni F, Canale ML, Borelli G, Rondinini L. Weight loss and quality of life in chronic heart failure patients. J Cardiovasc Med. 2008;9:576-80. (Pubitemid 351677697)
94. Peterson LR, Herrero P, Schechtman KB, Racette SB, Waggoner AD, Kisrieva-Ware Z, et al. Effect of obesity and insulin resistance on myocardial substrate metabolism and efficiency in young women. Circulation. 2004;109:2191-6. (Pubitemid 38625396)
95. Korvald C, Elvenes OP, Myrmel T. Myocardial substrate metabolism influences left ventricular energetics in vivo. Am J Physiol. 2000;278:H1345-51. (Pubitemid 30235514)
96. Lee J, Xu Y, Lu L, Bergman B, Leitner JW, Greyson C, et al. Multiple abnormalities of myocardial insulin signaling in a porcine model of diet-induced obesity. Am J Physiol. 2010;298:H310-9.
97. Alpert MA, Fraley MA, Birchem JA, Senkottaiyan N. Management of obesity cardiomyopathy. Expert Rev Cardiovasc Ther. 2005;3:225-30. (Pubitemid 40424941)
98. Verma S, McNeill JH. Metformin improves cardiac function in isolated streptozotocin-diabetic rat hearts. Am J Physiol. 1994;266:H714-9. (Pubitemid 24104818)
99. Borlaug BA, Nishimura RA, Sorajja P, Lam CSP, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. 2010;3:588-95.
100. Packer M. Role of the sympathetic nervous system in chronic heart failure. A historical and philosophical perspective. Circulation. 1990;82:I1-6.
101. Sverrisdottir YB, Rundqvist B, Johannsson G, Elam M. Sympathetic neural burst amplitude distribution: a more specific indicator of sympathoexcitation in human heart failure. Circulation. 2000;102:2076-81.
102. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. New Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
103. Straznicky NE, Grima MT, Eikelis N, Nestel PJ, Dawood T, Schlaich MP, et al. The effects of weight loss vs weight loss maintenance on sympathetic nervous system activity and metabolic syndrome components. J Clin Endocrinol Metab. 2011;96:E503-8.
104. Manzella D, Grella R, Esposito K, Giugliano D, Barbagallo M, Paolisso G. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration. Am J Hypertens. 2004;17:223-7. (Pubitemid 38293326)
105. DeBeck LD, Petersen SR, Jones KE, Stickland MK. Heart rate variability and muscle sympathetic nerve activity response to acute stress: the effect of breathing. Am J Physiol. 2010;299:R80-91.
106. Gudbjornsdottir S, Friberg P, Elam M, Attvall S, Lonnroth P, Wallin BG. The effect of metformin and insulin on sympathetic nerve activity, norepinephrine spillover and blood pressure in obese, insulin resistant, normoglycemic, hypertensive men. Blood Press. 1994;3:394-403. (Pubitemid 24380426)
107. Patel JN, Eisenhofer G, Coppack SW, Miles JM. Norepinephrine spillover in forearm and subcutaneous adipose tissue before and after eating. J Clin Endocrinol Metab. 1999;84:2815-9. (Pubitemid 30642592)
108. Kern W, Peters A, Born J, Fehm HL, Schultes B. Changes in blood pressure and plasma catecholamine levels during prolonged hyperinsulinemia. Metabolism. 2005;54:391-6. (Pubitemid 40250101)
109. Jeppesen J, Zhou M, Chen Y, Reaven G. Effect of metformin on postprandial lipemia in patients with fairly to poorly controlled NIDDM. Diabetes Care. 1994;17:1093-9. (Pubitemid 24307442)
110. Landsberg L. Feast or famine: the sympathetic nervous system response to nutrient intake. Cell Mol Neurobiol. 2006;26:497-508.
111. Viljanen APM, Karmi A, Borra R, Parkka JP, Lepomaki V, Parkkola R, et al. Effect of caloric restriction on myocardial fatty acid uptake, left ventricular mass, and cardiac work in obese adults. Am J Cardiol. 2009;103:1721-6.